Bryan Garnier - Onward Medical (ONWD.BR) ONWARD MEDICAL BUY | EUR17 Brain Spine Interface offers ONWARD entry into a highly sought-after market

Report

Bryan Garnier

Edward Hall

ONWARD MEDICAL BUY | EUR17 Brain Spine Interface offers ONWARD entry into a highly sought-after market

º Brain Spine Interface offers second-generation ARCIM potential
Competition shows limited bandwidth in physical restoration
Reiterate BUY and EUR 17 TP

20/06/2022 1 EN

Underlying

Onward Medical

See profile

Provider

Bryan Garnier

Since 1996, Bryan, Garnier & Co has been growing with an absolute conviction that the investment banking landscape would experience a major revolution: most of the large local generalist banking groups will disappear to the benefit of a handful of global powerhouses, and an emerging group of independent, highly specialised boutique investment banks.

See profile

Analysts

Edward Hall

Other Reports on these Companies

Bryan Garnier

ONWARD MEDICAL BUY | EUR17 It’s HemON!! H1 results in line and validation in sight

º Results in line with expectations with upside shown in catalyst timelines With clinical momentum building, we reiterate our Buy rating and EUR17 TP

September 27, 2022 September 27, 2022 1 EN

Bryan Garnier

ONWARD MEDICAL BUY | EUR17 The Up-LIFT we have been waiting for

This morning ONWARD’s reported pivotal Up-LIFT trial using ARCEX external Neurostimulation attained its primary endpoint at a clinical relevant threshold. This positive top-line data (stat. sig. in one function and strength endpoint) in the restoration of arm and hand function in patients paralysed in four limbs is likely to be filed in coming months, with further data being disclosed imminently. With key catalysts upcoming like i) Up-LIFT data presentation in the coming months, ii) observational data for Home use, and iii) STIMO-HEMO/Hem-ON data enrolling we expect this datapoint could be the...

September 14, 2022 September 14, 2022 1 EN

Carbios and Hündgen sign a MoU for feedstock supply

This morning, Carbios announced the signing of a non-binding Memorandum of Understanding with Hündgen, a waste management expect in logistics, sorting and recycling services. The MoU concerns the supply of 15kt/year of post-consumer PET waste to be recycled in the company's first commercial plant f

14h / 59m 14h / 59m 1 EN

Paul Charpentier

Paul Charpentier

Worldline - not as weak as expected, but too early to jump in

Worldline reported 2.5% organic growth in Q1 2024, weak in absolute terms but better than anticipated by the market and us. We wait for a clear uptick in momentum and the confirmation of an improved profitability to turn positive on the stock; which is arguably far from expensive at 5.1x EV/NTM EBI

15h / 17m 15h / 17m 1 EN

Cedric Rossi

Cedric Rossi

adidas: The best sunny terrace in sporting goods currently...

During the conference call, management tried to maintain a subtle equilibrium between presenting stronger-than-expected Q1 results and tempering somewhat analysts' optimism for FY24, as evidenced by a CSS estimate (EUR1.02bn) already standing well above ADS' revised guidance of "around EUR700m". We

15h / 35m 15h / 35m 1 EN

Sign-up for free to access full reports immediately

Email Address*

Choose Password* ( 6 or more characters )

Due to regulatory restrictions regarding the distribution of financial research, this report is restricted to a specific region or investor type. Get access to exclusive reports by answering the questions below.

Select your country*

Get financial insights straight to your inbox

By clicking "register" you accept the Terms and Conditions & Privacy Policy

Already on ResearchPool?

Almost there...

Are you a professional investor?

Select your country

REGISTER

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

In order to access this report please create an account.

LOGIN

ONWARD MEDICAL BUY | EUR17 Brain Spine Interface offers ONWARD entry into a highly sought-after market

ONWARD MEDICAL BUY | EUR17 It’s HemON!! H1 results in line and validation in sight

ONWARD MEDICAL BUY | EUR17 The Up-LIFT we have been waiting for

Carbios and Hündgen sign a MoU for feedstock supply

Worldline - not as weak as expected, but too early to jump in

adidas: The best sunny terrace in sporting goods currently...

Create a free ResearchPool account to access full reports, get a personalised dashboard and follow providers or companies

Sign-up for free to access full reports immediately

ResearchPool Subscriptions

Get the most out of your insights

Why subscribe?

How to subscribe

ResearchPool Subscriptions

This report is only available to subscribers

Why subscribe?

How to subscribe